KCNJ6 and cancer: Polymorphisms in the KCNJ6 gene affect pain responses by modifying the function of GIRK2 channels that regulate opioid receptors, leading to changes in pain tolerance and opioid efficacy and affecting treatment outcomes and quality of life for cancer patients [102].